Cargando…
A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
Among the many proposed therapeutic strategies for Huntington's disease (HD), allele-selective therapies are the most desirable but also the most challenging. RNA interference (RNAi) tools that target CAG repeats selectively reduce the mutant huntingtin level in cellular models of HD. The purpo...
Autores principales: | Kotowska-Zimmer, Anna, Przybyl, Lukasz, Pewinska, Marianna, Suszynska-Zajczyk, Joanna, Wronka, Dorota, Figiel, Maciej, Olejniczak, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126840/ https://www.ncbi.nlm.nih.gov/pubmed/35664700 http://dx.doi.org/10.1016/j.omtn.2022.04.031 |
Ejemplares similares
-
Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease
por: Van Raamsdonk, Jeremy M, et al.
Publicado: (2006) -
Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington’s disease are not reflected in mutant Huntingtin inclusion prevalence
por: Bayram-Weston, Zubeyde, et al.
Publicado: (2015) -
Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2018) -
Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease
por: de Paula Nascimento-Castro, Cristine, et al.
Publicado: (2022) -
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)